Gerresheimer, one of the founding partners of Connect in Pharma, will present its latest product solutions in the medical devices and packaging field at the premiere of the show that takes place on 14 to 15 September in Geneva.
A specialist lecture and a workshop will accompany the trade fair presentation. Gerresheimer will be present at Stand A20.
To meet the needs of patients and users, Gerresheimer is focusing on subcutaneous administration and the current landscape of delivery solutions for large-molecule biologics. In his presentation on September 14, Reza Abedian, senior medical affairs manager, will explain how this patient-centric approach can be implemented. In addition, patient preference information (PPI) will be explored both from a regulatory perspective and based on the results of two existing clinical trials.
Pharmaceutical and biotech companies focus on molecule discovery and development, but the delivery system is often not addressed in the development process. In the early stages of clinical development (Phase I+II), it can be beneficial to discuss different packaging options for the targeted patient populations, taking into account the challenges associated with drug molecules (concentration, dose, dry, liquid/liquid, etc.) and the associated manufacturing issues.
In the workshop on September 15, Wenzel Novak, senior global director, business development MDS and Jean-Edouard Rabier, project management director & sales development, Gx Biological Solutions, will share their experiences and insights. Likewise, specific solutions will be developed together with the participants.
Gerresheimer creates more direct access to its diverse product solutions for its customers and partners in the pharma, biopharma, and veterinary sectors through the gGuide. A specially developed algorithm is used to filter more than 1500 products from the company’s diverse pharma product areas on the basis of user input. The gGuide product selector combines the modern use of online advice with the highly valued expertise of the Gerresheimer team.
Based on SensAIR technology, the drug-device platform can deliver biologics such as monoclonal antibodies with different viscosities and large volumes of up to 20 ml.
The Gerresheimer autoinjector is the innovative result of the strategic partnership between Gerresheimer and Midas Pharma. The latest generation of the autoinjector is suitable for subcutaneous injections of up to 3 ml by means of a glass cartridge for high-viscosity formulations such as new biological active ingredients or biosimilars.
Nurses are among the occupational groups with the most frequent cuts and puncture wounds. This can lead to infections with dangerous pathogens such as hepatitis B and C or HIV. The Gx InnoSafe safety syringe is the first syringe on the market with a pre-installed passive needle protection system (RTF is thus implemented in a safety system for the first time). Its function prevents anyone from accidentally injuring themselves on a syringe that has already been used by an unintentional needle stick, as the needle is protected by a sleeve after use. The safety feature can be used on any existing RTF system without any further investment.
Gx Elite vials
The Gx Elite vials are the result of a careful, multi-year product development process. The highly shatterproof vials are extremely durable and free of cosmetic defects. They also have an incredibly robust structure, while their resistance to delamination protects the drug inside. Ease of use and a range of packaging options ensure that Gx Elite vials can be supplied for consistent use on a variety of filling lines.
Cyclic olefine polymer (COP) vials
COP packaging materials combine the best properties of plastic and glass packaging for liquid medications. Vials or syringes made of COP demonstrate better compatibility with specific drug products when compared with glass vials and syringes. This is especially the case when the drug formulation has an extremely high pH value, which would attack the glass surface or when the drug product is sensitive to metal ions that can leach from the glass matrix.
Several deep-freeze studies have found that COP vials are a recommendable container-closure system (CCS) for drug products that have to be stored at a temperature of -80°C or below as it keeps the integrity during the deep-freeze temperature. Such COP-based packaging is the best option for the next generation of gene and cell drug products.